(Q40044243)

16 September 2017

title

Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro (English)

1 reference

16 September 2017

Arpita Chakravarti

1

1 reference

16 September 2017

Andrée-Anne Marceau

series ordinal

2

1 reference

16 September 2017

Louis Flamand

series ordinal

3

1 reference

16 September 2017

Patrice E Poubelle

series ordinal

4

1 reference

16 September 2017

publication date

26 November 2007

1 reference

16 September 2017

published in

Laboratory Investigation

1 reference

16 September 2017

volume

88

1 reference

16 September 2017

issue

2

1 reference

16 September 2017

page(s)

171-184

1 reference

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

The immunopathogenesis of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Determination of IL1 alpha, IL1 beta and IL2 in biological media using specific enzyme immunometric assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

The CD4-gp120 interaction and AIDS pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Cytokines and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Effects of activated T cells on osteoclastogenesis depend on how they are activated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Il-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Reduced bone mineral density in HIV-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

Inhibition of the expression and function of chemokine receptors on human CD4+ leukocytes by HIV-1 envelope protein gp120.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

T Cell Activation Induces Human Osteoclast Formation via Receptor Activator of Nuclear Factor κB Ligand-Dependent and -Independent Mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700701

7 January 2021

10.1038/LABINVEST.3700701

Identifiers

DOI

1 reference

16 September 2017

1 reference